Welcome to our dedicated page for ImageneBio SEC filings (Ticker: IMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ImageneBio, Inc. filings document a Nasdaq-listed biotechnology issuer focused on IMG-007, its anti-OX40 receptor antagonist program for autoimmune and inflammatory diseases. Its 8-K reports disclose operating results, program updates, Regulation FD materials, private-placement and capital-structure matters, and officer or director changes.
Proxy materials cover annual meeting proposals, director elections, auditor ratification, equity incentive plan amendments, and executive compensation governance. The filing record also identifies the company’s common stock on The Nasdaq Capital Market and records formal disclosures tied to its completed reverse-merger corporate history.
ImageneBio, Inc. Schedule 13G/A discloses that a group of related entities led by Biotechnology Value Fund and Mark N. Lampert collectively report beneficial ownership positions in the company's common stock. The filing lists specific holdings as of March 31, 2026 and cites an outstanding share base of 11,184,995 shares as of March 2, 2026.
The filing itemizes holdings by entity: BVF 593,189 shares (≈5.3%), BVF2 433,269 shares (≈3.9%), Trading Fund OS 66,808 shares (<1%), and aggregate positions attributed across affiliated entities up to 1,110,002 shares (≈9.9%). Voting and dispositive power are disclosed as shared among the listed reporting persons.
Blue Owl Capital Holdings filed Amendment No. 1 to a Schedule 13G/A reporting beneficial ownership in ImageneBio, Inc.
The filing states the Reporting Person beneficially owns 959,337 shares of Common Stock, equal to 8.51% of the class, calculated using 11,279,130 shares outstanding as of April 30, 2026 (per the issuer's 10-Q filed May 7, 2026). The cover page lists sole voting and dispositive power over the 959,337 shares. The statement includes a Rule 13d-4 declaration that filing is not an admission of beneficial ownership.
ImageneBio, Inc. files a prospectus supplement to register 2,508,337 shares of Common Stock for offer and resale by identified selling stockholders. The supplement updates the April 2, 2026 prospectus with selected Form 10-Q information and notes a last reported sale price of $6.08 per share on May 6, 2026.
The registration relates to resale or other dispositions "from time to time by the selling stockholders" under Registration No. 333-290108; the supplement is dated May 7, 2026 and references the Prospectus dated April 2, 2026.
ImageneBio, Inc. registers 2,508,337 shares of Common Stock for resale by the selling stockholders identified in the prospectus supplement. The resale prospectus supplement updates the Form S-1 registration (No. 333-290108) and incorporates specified portions of the company’s Form 10-Q filed May 7, 2026.
The Common Stock trades on the Nasdaq Capital Market under the symbol IMA; the last reported sales price on May 6, 2026 was $6.08 per share. The prospectus supplement states proceeds from resales will be received by the selling stockholders, not the issuer.
ImageneBio, Inc. is a clinical-stage biopharmaceutical company focused on immunological and inflammatory diseases, led by its anti-OX40 antibody IMG-007 for atopic dermatitis and alopecia areata. For the three months ended March 31, 2026, it reported a net loss of $10.6 million, compared with $6.1 million a year earlier, as research and development expenses rose to $6.0 million and general and administrative expenses increased to $6.1 million.
Cash, cash equivalents and marketable securities totaled $117.2 million as of March 31, 2026. In April 2026, the company raised an additional $30.0 million through a private placement of pre-funded warrants to purchase up to 5,770,335 shares of common stock at a purchase price of $5.199 per warrant share and an exercise price of $0.001 per share. Management believes this funding, together with existing resources, can support operations for at least 12 months.
The company completed a reverse merger with Ikena Oncology and divested its non-OX40 assets in 2025, leaving IMG-007 as its sole clinical asset. A multi-country Phase 2b dose-finding study in atopic dermatitis is underway, with topline data expected in the fourth quarter of 2027, and a Phase 2 study in alopecia areata is planned to start by the end of 2026, with initial data anticipated in 2028.
ImageneBio, Inc. reported first quarter 2026 results and highlighted progress for its lead OX40 antibody IMG-007 in atopic dermatitis and alopecia areata. License revenue was $0 versus $800,000 a year earlier as the company focuses on clinical development.
Research and development expenses rose to $6.0 million from $4.0 million, and general and administrative expenses increased to $6.1 million from $2.8 million. Net loss widened to $10.6 million from $9.1 million, reflecting higher operating costs.
Imagene ended March 31, 2026 with $117.2 million in cash, cash equivalents, and marketable securities and subsequently completed a $30 million private placement of pre-funded warrants. The company states this financing extends its cash runway into the first quarter of 2028 while it advances the Phase 2b ADAPTIVE trial of IMG-007 in atopic dermatitis and continues development in alopecia areata.
ImageneBio, Inc. is holding a virtual 2026 Annual Meeting on June 16, 2026, for stockholders of record as of April 28, 2026. Stockholders will vote on electing two Class II directors, ratifying PricewaterhouseCoopers LLP as auditor for 2026, and approving an amended 2025 Equity Incentive Plan.
The equity plan amendment would add 850,000 shares to the plan and revise its evergreen formula to factor in shares issuable upon conversion of preferred stock and cash exercise of prefunded warrants. As of April 28, 2026, 11,279,130 shares of common stock were outstanding, and equity awards included 1,187,218 options and 652,517 restricted stock units.
The proxy describes ImageneBio’s post‑merger governance structure, with a classified board, a non‑executive chair, a lead independent director, fully independent key committees, and policies covering risk oversight, insider trading, hedging, and director independence. It also details audit fees and confirms prior auditor transition from Ernst & Young LLP to PricewaterhouseCoopers LLP.
OrbiMed Advisors LLC and affiliated funds filed Amendment No. 6 to their Schedule 13D on ImageneBio, Inc. common stock. The filing reflects purchases of pre-funded warrants in the company’s 2026 private placement (2026 PIPE) and updates OrbiMed’s beneficial ownership.
OrbiMed now reports beneficial ownership of 1,495,045 Shares, including 721,292 Shares underlying presently exercisable Pre-Funded Warrants, representing 13.1% of ImageneBio’s 11,375,573 outstanding Shares. OrbiMed Private Investments VI, LP holds 1,089,665 Shares (including 336,603 Pre-Funded Warrants) and OrbiMed Genesis Master Fund, L.P. holds 405,380 Shares (including 384,689 Pre-Funded Warrants). A separate client, Worldwide Healthcare Trust PLC, holds 135,516 Shares. The 2026 PIPE Pre-Funded Warrants are priced at $5.199 each and include a 19.99% ownership blocker.
ImageneBio (Common Stock) is reported as having an aggregate of 1,176,472 shares beneficially owned by Trails Edge entities and Ortav Yehudai as of April 14, 2026. That holding comprises 54,253 shares held directly and 1,122,219 shares issuable upon pre-funded warrants, and is stated as 9.9% of the class based on 10,654,281 shares outstanding as of March 2, 2026.